Literature DB >> 32616192

Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.

Yu-Chi Chen1, Mu-Yang Huang1, Le-Le Zhang2, Zhe-Ling Feng1, Xiao-Ming Jiang1, Luo-Wei Yuan1, Run-Yue Huang3, Bo Liu3, Hua Yu1, Yi-Tao Wang1, Xiu-Ping Chen1, Li-Gen Lin1, Jin-Jian Lu4.   

Abstract

Nagilactone E (NLE), a natural product with anticancer activities, is isolated from Podocarpus nagi. In this study, we reported that NLE increased programmed death ligand 1 (PD-L1) expressions at both protein and mRNA levels in human lung cancer cells, and enhanced its localization on the cell membrane. Mechanistically, NLE increased the phosphorylation and expression of c-Jun, and promoted the localization of c-Jun in the nucleus, while silencing of c-Jun by small interfering RNA (siRNA) reduced NLE-induced PD-L1. Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1. Moreover, NLE-induced PD-L1 increased the binding intensity of PD-1 on the cell surface. In summary, NLE upregulates the expression of PD-L1 in lung cancer cells through the activation of JNK-c-Jun axis, which has the potential to combine with the PD-1/PD-L1 antibody therapies in lung cancer.
Copyright © 2020 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  JNK; Lung cancer; Nagilactone E; Programmed death ligand 1; c-Jun

Year:  2020        PMID: 32616192     DOI: 10.1016/S1875-5364(20)30062-5

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  5 in total

1.  c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.

Authors:  Min-Xia Su; Yu-Lian Xu; Xiao-Ming Jiang; Mu-Yang Huang; Le-Le Zhang; Luo-Wei Yuan; Xiao-Huang Xu; Qi Zhu; Jian-Li Gao; Jia-Hong Lu; Xiuping Chen; Ming-Qing Huang; Yitao Wang; Jin-Jian Lu
Journal:  Acta Pharm Sin B       Date:  2021-09-22       Impact factor: 14.903

Review 2.  Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.

Authors:  Richard Kwamla Amewu; Patrick Opare Sakyi; Dorcas Osei-Safo; Ivan Addae-Mensah
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

3.  Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: A new platform for synergistic oncology therapy.

Authors:  Xiaobei Cheng; Pei Yu; Xiang Zhou; Jiale Zhu; Yubao Han; Chao Zhang; Lingyi Kong
Journal:  Acta Pharm Sin B       Date:  2021-08-21       Impact factor: 11.413

4.  Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells' Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway.

Authors:  Xianfeng Chen; Juntao Hu; Jie Lai; Zhiyong Zhang; Zhanhong Tang
Journal:  Can Respir J       Date:  2022-07-31       Impact factor: 2.130

Review 5.  Biological Activity of Selected Natural and Synthetic Terpenoid Lactones.

Authors:  Alicja K Surowiak; Lucyna Balcerzak; Stanisław Lochyński; Daniel J Strub
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.